NEW
Stock Screener with Intrinsic Value
Alnylam Pharmaceuticals, Inc. (ALNY)
Last Price$238.0(1.1%)
Market Cap$30.1B
DCF value
N/A
Overvalued (DCF value)
(100.0%)
Discount Rate
7.8%
Long-Term Growth Rate
3.0%
Stock quality
6/10
Good
ALNY DCF Model
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
ALNY DCF Value
Crunching data... Almost there!
ALNY DCF Financials
Crunching data... Almost there!
ALNY DCF sensitivity
Crunching data... Almost there!
Explore more intrinsic value tools hub for ALNY
Margin of safety
Peter Lynch charts
Ben Graham Fair Value
Earnings Power Value
Relative Value
Earnings growth model
Discount rate
Peter Lynch Fair Value
Intrinsic Value
Reverse DCF
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Alnylam Pharmaceuticals, Inc. DCF (discounted cash flow) valuation?
As of Jan 10, 2025, Alnylam Pharmaceuticals, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by (100.0%) compared to its current price of around $238.0, using a WACC of 7.8% and growth rates of 3.0%.
What is Alnylam Pharmaceuticals, Inc. WACC?
As of Jan 10, 2025, Alnylam Pharmaceuticals, Inc.'s Weighted Average Cost of Capital (WACC) is approximately 7.8%.
What is Alnylam Pharmaceuticals, Inc. Enterprise Value?
As of Jan 10, 2025, Alnylam Pharmaceuticals, Inc.'s Enterprise Value (EV) is approximately $0.0. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.